Palo Alto, Calif.-based Varian Medical Systems will acquire Sirtex Medical Ltd. for about A$1.6 billion (US$1.3 billion). Shares of the acquirer remained flat on the announcement, perhaps because the deal was viewed as somewhat predictable and expensive by investors. Varian also recently had a share price bounce of about 13 percent on better-than-expected performance in its Jan. 24 earnings. Read More

PERTH, Australia – Australian biotech company Patrys Ltd. is developing an antibody that can enter the cell nucleus. If clinical trials go well, it would be a game-changer, because it would mean that intracellular targets could be accessible to antibodies. Read More

HONG KONG – The elucidation of the detailed three-dimensional (3-D) atomic structure of a key drug receptor will facilitate the design of new polypharmacology drugs capable of acting on multiple targets, opening up new ways to develop drugs for the treatment of complex diseases. Read More

HONG KONG – An 11-year-old Chinese biopharma company has recently entered the public's eye with a $10 million series A funding and a clinical trial approval by the CFDA for its biosimilar etanercept. Read More

Cellular Biomedicine Group Inc., of Shanghai, said it received a $30.6 million investment from Sailing Capital Overseas Investment Ltd. and its affiliates, a global private equity firm focused on China cross-border investments. The company said it has demonstrated clinical proof of concept of a CAR T-cell immuno-oncology platform and the current investment will enable its further clinical development. Read More